FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
42 letters match. Newest first.
-
DrugsShenzhen Benliju Biotech Co., Ltd.
FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.
High risk -
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsNorthland Nuclear Medicine, LLC
FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.
High risk -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsJiangmen Shuizirun Sanitary Articles Co., Ltd.
FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.
High risk -
AnimalSciarra Aeromed, Inc.
Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.
High risk -
AnimalNeogen Corporation
FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.
High risk -
BiologicsNexCell Scientific Inc
NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.
High risk -
DrugsPReye, LLC
FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.
High risk -
BiologicsR3 Medical Companies
FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
BiologicsGenzyme Ireland Limited
Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsVivioMD Group LLC dba VivioMD
FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.
Low -
DrugsNexlife Inc. dba Nexlife
FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsSato Pharmaceutical Co., Ltd.
FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.
High risk -
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsUCSF Radiopharmaceutical Facility
FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.
High risk -
DrugsRC Outsourcing, LLC
FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.
High risk -
DrugsThrive Health and Wellness, LLC dba Thrive Health Solutions
FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.
High risk -
DrugsApollo Care, LLC
FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.
High risk -
DrugsSimtra BioPharma Solutions
FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.
High risk -
DrugsNSE Products, Inc. DBA Nu Skin Enterprises, Inc.
FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsNewSelf Limited dba NewSelf
FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
Low -
DrugsBelle Health LLC dba Belle
FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
Low -
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsBio-Medical Pharmaceutical Manufacturing Corporation
Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.
High risk -
BiologicsConceive Fertility Center
FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk